Latest Abatacept Stories
EXTON, Pa., Dec. 20, 2010 /PRNewswire/ -- In its recently released annual 2010 update, ChartTrendsÂ®: Biologics in Rheumatoid Arthritis, BioTrends Research Group, Inc.
Today, individuals with lupus nephritis benefit from better treatments than a decade ago.
Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE).
EXTON, Pa., Jan. 11 /PRNewswire/ -- BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrendsÂ®: ACTEMRA. Roche, Inc. announced that they received FDA approval for Actemra (generic name: tocilizumab) on January 8th.
EXTON, Pa., Dec. 14 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrendsÂ®: Biologics in Rheumatoid Arthritis, a syndicated publication offering comprehensive insight into the management of RA patients.
Abatacept, a member of a new class of drug that targets immune cells to treat rheumatoid arthritis (RA), is effective against RA, according to a new Cochrane Systematic Review.
WALTHAM, Mass., Aug. 6 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the first quarter fiscal year 2010, ended June 30, 2009. Total revenue for the quarter was $5,061,000 compared to total revenue of $13,660,000 for the first quarter of fiscal year 2009.
WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed rheumatologists' perception of Bristol-Myers Squibb's Orencia is low among rheumatoid arthritis agents.
University of Maryland researchers see potential new treatment approach in targeting immune response to virus.
Recent Entrants Invest Heavily in Promotion to Capture Share in Mature Market, According to a New Report from Decision Resources WALTHAM, Mass., Jan.
- Growing in low tufty patches.